Why the study?
Does molsidomine improve antianginal and antiischemic activity in patients with stable angina pectoris?
Does molsidomine improve antianginal and antiischemic activity in patients with stable angina pectoris?
Molsidomine demonstrates antianginal and antiischemic efficacy in patients with stable angina pectoris over a 3-month period.
Answers are grounded in this paper and cite their sources.
May support molsidomine for angina relief in stable CAD; leaves open need for randomized confirmation.
Aim. To evaluate antianginal and antiischemic activity of molsidomine (Corvaton) in stable angina pectoris of II-III functional class (FC). Material and methods. 45 patients with II FC (31 persons) and III FC of angina (14 persons) were included into the study. All patients took molsidomine in individual doses during 3 months. Antianginal and antiischemic activity of molsidomine was estimated by veloergometric tests. Results. Molsidomine therapy resulted in disappearance of angina pectoris in 41, 7% of patients with stable angina of II-III FC and reduction of ST depression. Conclusion. Molsidomine is an effective antianginal and antiischemic medicine in patients with stable angina of II-III FC and provides the stable effect during long-term usage.
No takes yet. Share an insight, caveat, or question.
Sinitsina et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: